V7B Stock Chart & Stats
€25.50
-€0.10(-0.62%)
At close: 4:00 PM EST
€25.50
-€0.10(-0.62%)
Day’s Range― - ―
52-Week Range€15.05 - €33.50
Previous CloseN/A
Volume700.00
Average Volume (3M)158.00
Market Cap
€465.42M
Enterprise Value€244.87
Total Cash (Recent Filing)€226.60M
Total Debt (Recent Filing)€2.49M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 12, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding19,817,250
10 Day Avg. Volume188
30 Day Avg. Volume158
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.21Price Target Upside57.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.49
Revenue Forecast (FY)€39.79M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageExtremely low leverage and substantial equity provide Assembly financial flexibility to fund multi-stage clinical programs without a heavy interest burden. A sturdy balance sheet reduces near-term solvency risk and supports continued R&D investment as trials progress.
Completed $107M Equity Raise; Institutional SupportThe ~$107.4M net proceeds materially extend runway to advance planned Phase 2 studies and program expansion. Participation by healthcare investors including Gilead signals external validation and lowers immediate refinancing risk for upcoming clinical milestones.
Pipeline Expansion Into Cholestatic Liver DiseasesExpanding ABI-6250 into PBC and PSC diversifies the pipeline into areas with high unmet need and few approved options. FDA pre-IND engagement and scheduled Phase 2 starts increase program optionality and potential long-term commercial differentiation if trials confirm safety and efficacy.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow (~-$39.8M TTM) and steep FCF decline mean the company requires ongoing external funding to sustain operations. This dynamic pressures runway, forces reliance on dilutive raises or partnerships, and constrains long-term strategic flexibility.
No Commercial Product Revenue; Funding RelianceAs a clinical-stage firm without commercial products, Assembly depends on collaborations, milestone payments and capital markets to fund R&D. This funding dependence elevates execution risk, ties progress to partner timing, and makes sustainable growth contingent on successful trial outcomes or deals.
Volatile Revenue And Negative ProfitabilitySharp revenue decline and persistent negative net margins reflect volatile, milestone-driven income and lack of operating profitability. Unstable top-line and losses complicate forecasting and investment planning, increasing the company's exposure to funding cycles and trial risks.
Assembly Biosciences News
V7B FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was €15.05 and its highest was €33.50 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is €465.42M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on May 07, 2026. The company reported -€0.473 earnings per share for the quarter, beating the consensus estimate of -€0.569 by €0.096.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.63.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 19,817,250 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -€0.473 in its last earnings report, beating expectations of -€0.569. Following the earnings report the stock price went down -1.321%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in DE:V7B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.21 (57.68% Upside)
€40.21 (57.68% Upside)
Insider Transactions
Sold Shares
Worth €589.6 over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
144.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
137.85%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
V7B Stock 12 Month Forecast
Average Price Target
€40.21
▲(57.68% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―